Bococizumab (PF-04950615; RN316)

DRUG3 trials

Sponsors

Pfizer

Conditions

HypercholesterolemiaHyperlipidemia

Phase 1

Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

CompletedNCT02043301

PfizerHypercholesterolemia

Start: 2014-04-30End: 2014-11-30Updated: 2019-05-31

Phase 3

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

CompletedNCT01968967

PfizerHyperlipidemia

Start: 2013-10-29End: 2017-07-10Updated: 2018-07-31

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

CompletedNCT02100514

PfizerHyperlipidemia

Start: 2014-10-28End: 2017-07-10Updated: 2018-07-31

Related Papers

Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1

Scientific Reports2022-03-116 citations

Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.

2018-04-0347 citations

Abstract 23073: Cardiovascular Efficacy of PCSK9 Inhibition Among 1,578 Patients With Familial Hypercholesterolemia: The SPIRE Clinical Trials FH Analysis

Circulation2017-11-141 citations

Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301].

2017-10-019 citations

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

New England Journal of Medicine2017-03-17355 citations